

October 20, 2022

✓ BSE Limited

Department of Corporate Services, P. J. Towers, Dalal Street, Mumbai Samachar Marg, <u>MUMBAI - 400 001</u>.

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex, Bandra (East), <u>MUMBAI - 400 051</u>.

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

We are pleased to inform you that Lupin Inc., USA, wholly owned subsidiary of the Company, has signed Definitive Agreement with Sunovion Pharmaceuticals Inc., USA for acquiring Brovana® and Xopenex HFA®, respiratory brands. In this regard, in compliance with Regulation 30 read with Schedule III of the Listing Regulations and SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015, we are pleased to provide the following particulars: -

Name of the Acquirer - Lupin Inc., USA

a)	name of the target entity, details in brief such as size, turnover etc.;	Lupin Inc. is purchasing all assets required to manufacture and commercialize Brovana® (Arformoterol Tartrate) Inhalation Solution and Xopenex HFA® (Levalbuterol Tartrate) Inhalation Aerosol in the United States.
b)	whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length";	No.
c)	industry to which the entity being acquired belongs;	Pharmaceuticals.
d)	objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Expands Lupin's portfolio of Inhalation products.
e)	brief details of any governmental or regulatory approvals required for the acquisition;	None.
f)	indicative time period for completion of the acquisition;	Acquisition is expected to be completed 2-3 weeks post signing.



g)	nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration.
h)	cost of acquisition or the price at which the shares are acquired;	Purchase price is USD 75 Mn.
i)	percentage of shareholding/control acquired and/or number of shares acquired;	Not applicable, since acquisition is of brands.
j)	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	IQVIA sales for the two brands combined were approximately \$60 Million (MAT August 2022).

We are pleased to enclose a Press Release in connection with the acquisition.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

R. V. SATAM COMPANY SECRETARY (ACS -1 1973)

Encl: a/a



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

Lupin Signs Agreement to Acquire Two Inhalation Brands from Sunovion

Mumbai, Naples, October 20, 2022: Global pharmaceutical major Lupin Limited (Lupin) today announced signing of an agreement to acquire all rights to two inhalation medicines, Brovana[®] (arformoterol tartrate) Inhalation Solution and Xopenex HFA[®] (levalbuterol tartrate) Inhalation Aerosol, from Sunovion Pharmaceuticals Inc. (Sunovion) for a purchase price of \$75 million. Lupin expects the transaction to be accretive to earnings in the first year.

The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S. and strengthens the company's presence in the respiratory therapy area while continuing to provide patients access to these important medicines. Brovana is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Xopenex HFA is a short-acting beta2-adrenergic agonist (SABA) indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age or older with reversible obstructive airway disease.

Vinita Gupta, CEO, Lupin said "We remain focused on strengthening our respiratory franchise in the U.S. We have established a strong position in the respiratory segment with our Albuterol MDI and Brovana authorized generic launch. The addition of these two brands enhances our position in the segment."

--

About Lupin


Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit <u>www.lupin.com</u> for more information.

Follow us on Twitter: <u>https://twitter.com/LupinGlobal</u>|LinkedIn: <u>https://www.linkedin.com/company/lupin</u> Facebook: <u>http://www.facebook.com/LupinWorld/</u>



For further information or queries please contact:

Shweta Munjal

Vice President & Global Head – Corporate Communications Email: <u>shwetamunjal@lupin.com</u>